Endometriosis: Chronic Pain, Daily Struggles

One in ten women worldwide are affected by #endometriosis. For many of them, it is an extremely painful condition, with both chronic and acute pain disrupting their everyday life. As a consequence, many women with endometriosis face challenges at work, in their studies, with friends and family, and in other social situations.

Painful periods are often the first symptom of endometriosis.   Learn more about endometriosis and its symptoms, and find your nearest support group: https://endometriosis.org/

March is Endometriosis Awareness Month. Gesynta Pharma is dedicated to the development of better treatments for endometriosis patients.


Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

The members of Gesynta Pharma's management team and board of directors have extensive experience from drug development and commercialization.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II for endometriosis, while GS-073 is ready to enter clinical phase I for chronic inflammatory pain.